Who Paid My Doc
Daniel Cosgrove
Public Health & General Preventive Medicine Indian Wells, CA Medical Doctor
NPI 1235257429 CMS profile 237619
45200 Club Dr Ste A, Indian Wells, CA 92210
General payments
$61,284
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Cosgrove of Indian Wells, CA is reported in the CMS Open Payments database as having received $61,284 across 153 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Public Health & General Preventive Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $12,750 | 22 | |
| 2024 | General | $25,391 | 34 | |
| 2023 | General | $11,492 | 30 | |
| 2022 | General | $6,254 | 29 | |
| 2021 | General | $4,866 | 24 | |
| 2020 | General | $129 | 5 | |
| 2019 | General | $403 | 9 |
Beside peers
- Daniel Cosgrove
- Public Health & General Preventive Medicine median
- Middle half of Public Health & General Preventive Medicine
- National median
In program year 2025, general payments to Daniel Cosgrove were reported at $12,750. Among 185 Public Health & General Preventive Medicine profiles paid that year, the median was $99 and the middle half received between $32 and $365.
Show as a table
| Year | Daniel Cosgrove | Public Health & General Preventive Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $403 | $99 | $22–$287 | $163 |
| 2020 | $129 | $101 | $21–$478 | $114 |
| 2021 | $4,866 | $99 | $31–$856 | $132 |
| 2022 | $6,254 | $79 | $24–$340 | $149 |
| 2023 | $11,492 | $102 | $28–$326 | $160 |
| 2024 | $25,391 | $98 | $27–$291 | $164 |
| 2025 | $12,750 | $99 | $32–$365 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 45 drugsPart D claims
990
Drug cost
$313,412
Branded share of claims
36.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 11 | $80,770 | |
| Repatha Sureclick Evolocumab | Brand | 87 | $66,522 | |
| Genotropin Somatropin | Brand | 25 | $64,474 | |
| Eliquis Apixaban | Brand | 27 | $34,669 | |
| Ozempic Semaglutide | Brand | 25 | $29,475 | |
| Praluent Pen Alirocumab | Brand | 19 | $12,346 | |
| Buprenorphine | Generic | 12 | $5,325 | |
| Testosterone | Generic | 39 | $2,686 | |
| Estradiol (Twice Weekly) Estradiol | Brand | 27 | $2,026 | |
| Levothyroxine Sodium | Generic | 32 | $1,217 |
The 10 drugs with the highest cost, of 45 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 6 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Wegovy |
|
$118 | — | — |
| LEQVIO |
|
$82 | — | — |
| Otezla |
|
$71 | — | — |
| Repatha |
|
$71 | 87 | — |
| Leqembi |
|
$38 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 6 in the dashboard with a free accountRecords
153 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Public Health & General Preventive Medicine in California
Steven Galson
Public Health & General Preventive Medicine · Thousand Oaks, CA
Ryan Zane
Public Health & General Preventive Medicine · San Bernardino, CA
Ross Miller
Public Health & General Preventive Medicine · Beverly Hills, CA
Philp Darney
Public Health & General Preventive Medicine · San Francisco, CA
Karen Studer
Public Health & General Preventive Medicine · Loma Linda, CA
George Rutherford
Public Health & General Preventive Medicine · San Francisco, CA
Related records
Public Health & General Preventive Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Public Health & General Preventive Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.